Your browser doesn't support javascript.
loading
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Li, Shangze; Fong, Ka-Wing; Gritsina, Galina; Zhang, Ali; Zhao, Jonathan C; Kim, Jung; Sharp, Adam; Yuan, Wei; Aversa, Caterina; Yang, Ximing J; Nelson, Peter S; Feng, Felix Y; Chinnaiyan, Arul M; de Bono, Johann S; Morrissey, Colm; Rettig, Matthew B; Yu, Jindan.
Afiliação
  • Li S; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Fong KW; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Gritsina G; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Zhang A; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Zhao JC; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Kim J; Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • Sharp A; Institute of Cancer Research, London, United Kingdom.
  • Yuan W; Royal Marsden Hospital, London, United Kingdom.
  • Aversa C; Institute of Cancer Research, London, United Kingdom.
  • Yang XJ; Institute of Cancer Research, London, United Kingdom.
  • Nelson PS; Royal Marsden Hospital, London, United Kingdom.
  • Feng FY; Department of Pathology, Northwestern University, Chicago, Illinois.
  • Chinnaiyan AM; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
  • de Bono JS; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Morrissey C; Departments of Radiation Oncology, Urology, and Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
  • Rettig MB; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
  • Yu J; Institute of Cancer Research, London, United Kingdom.
Cancer Res ; 79(10): 2580-2592, 2019 05 15.
Article em En | MEDLINE | ID: mdl-30952632

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Resistencia a Medicamentos Antineoplásicos / Sistema de Sinalização das MAP Quinases / Receptores CXCR / Neoplasias de Próstata Resistentes à Castração / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Cancer Res Ano de publicação: 2019 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Resistencia a Medicamentos Antineoplásicos / Sistema de Sinalização das MAP Quinases / Receptores CXCR / Neoplasias de Próstata Resistentes à Castração / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Cancer Res Ano de publicação: 2019 Tipo de documento: Article País de publicação: Estados Unidos